EUVIMEDEUVIMED entdecken
Crossref

Orally Antigen-Engineered Yeast Vaccine Elicits Robust Intestinal Mucosal Immunity

Xuenian Chen, Tongfei Shi, Fangman Chen iD, Xiaochun Xie, Hui Fang, Ziping Wu, Yang Liu, Yubiao Huang, Qin Wang, Guangjun Nie iD, Jiaqi Xu iD, Dan Shao iD

ACS Nano · 25.03.2025 · 19 (11) · 10841-10853

DOI: 10.1021/acsnano.4c14690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 13.03.2025. Verfasst von Xuenian Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, P.R. China. Hauptthemen laut MEDLINE: Intestinal Mucosa, Immunity, Mucosal, COVID-19 Vaccines, Saccharomycetales. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Beijing Municipal Natural Science Foundation, National Natural Science Foundation of China, Science and Technology Program of Guangzhou, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucosal immunity plays a pivotal role in safeguarding against significant global infectious diseases caused by mucosal pathogens. The development of mucosal vaccines has been limited by the poor efficiency of antigen display and the risk of adjuvants. Here, we report an engineered yeast vaccine integrating a well-displayed antigen with an intrinsic adjuvant for the development of innate and adaptive immunity to the intestinal mucosa. Compared with antigen-secretory yeast, antigen-anchored yeast significantly activated gut dendritic cells (DCs) and promoted follicular helper T (Tfh) cell differentiation, thereby amplifying the immune response by the interaction with Tfh-B cells. Consequently, oral vaccination of SARS-CoV-2 receptor-binding domain (RBD)-anchored yeast triggered stronger RBD-specific IgA-neutralizing effects, providing potential adaptive protections. Given its corresponding impact on the functionality of both innate and adaptive mucosal responses, the proposed RBD-anchored yeast outperformed RBD-anchored bacteria and biomimetic nanovaccine in the production of RBD-specific IgA and IgG. Together, these results revealed how antigen-displaying patterns could be modulated to elicit intestinal mucosal immunity and demonstrated the translational potential of antigen-displayed yeast for effective mucosal protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal MucosaImmunity, MucosalCOVID-19 VaccinesSaccharomycetalesImmunogenicity, VaccineSpike Glycoprotein, CoronavirusDendritic CellsT-Lymphocytes, Helper-InducerAntibodies, NeutralizingImmunoglobulin APeyer's PatchesLymph NodesMesenteryFemaleAnimalsMiceMice, Inbred BALB CVaccines, SyntheticAdministration, Oral

Stichwörter der Autor:innen

antigen-displayingmucosal immunityoral administrationvaccineyeast

Substanzen

COVID-19 VaccinesAntibodies, NeutralizingImmunoglobulin AVaccines, Syntheticspike protein, SARS-CoV-2Spike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • School of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, P.R. China.
  • School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong 511442, P.R. China.
  • National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, Guangdong 510006, P.R. China.
  • School of Nanoscience and Engineering, University of Chinese Academy of Sciences, Beijing 101408, P.R. China.
  • Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China.
  • CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, P.R. China.

ORCID-Profile: Fangman Chen, Guangjun Nie, Jiaqi Xu, Dan Shao

Förderung

  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China
  • Science and Technology Program of Guangzhou, China

Zitieren

APA

Chen, X., Shi, T., Chen, F., Xie, X., Fang, H., Wu, Z., Liu, Y., Huang, Y., Wang, Q., Nie, G., Xu, J., & Shao, D. (2025). Orally Antigen-Engineered Yeast Vaccine Elicits Robust Intestinal Mucosal Immunity. ACS Nano, 19(11), 10841-10853. https://doi.org/10.1021/acsnano.4c14690

Vancouver

Chen X, Shi T, Chen F, Xie X, Fang H, Wu Z, et al. Orally Antigen-Engineered Yeast Vaccine Elicits Robust Intestinal Mucosal Immunity. ACS Nano. 2025;19(11):10841-10853. doi:10.1021/acsnano.4c14690

BibTeX
@article{Chen2025,
  author = {Chen, Xuenian and Shi, Tongfei and Chen, Fangman and Xie, Xiaochun and Fang, Hui and Wu, Ziping and Liu, Yang and Huang, Yubiao and Wang, Qin and Nie, Guangjun and Xu, Jiaqi and Shao, Dan},
  title = {Orally Antigen-Engineered Yeast Vaccine Elicits Robust Intestinal Mucosal Immunity},
  journal = {ACS Nano},
  year = {2025},
  volume = {19},
  number = {11},
  pages = {10841--10853},
  doi = {10.1021/acsnano.4c14690}
}
Kostenlos starten →